Clinical Trial

S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them after surgery may kill any remaining tumor cells. It is not yet known which combination chemotherapy regimen is more effective in treating resected breast cancer. PURPOSE: This randomized phase III trial is comparing 2 different regimens of combination chemotherapy to see how well they work in treating patients who have undergone surgery for stage I, stage II, or stage III breast cancer.
Protocol Amendment History 822 amendments
This ClinicalTrials.gov record has been amended 822 times since 2005-06-23; most recent amendment 2025-07-29.
Status change: Recruiting → Active, Not Recruiting 2012-01-17
Status change: Suspended → Recruiting 2010-12-18
Status change: Recruiting → Suspended 2010-11-12
Trial Details
NCT Number NCT00070564
Lead Sponsor SWOG Cancer Research Network
Collaborators: National Cancer Institute (NCI)
Conditions Breast Cancer
Enrollment 3,294 participants
Start Date 2003-11
Primary Completion 2015-01 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2025-07-31